Blackstone, Carlyle, KKR Eye $11 Billion Buyout

Apr 10 2013 | 10:28am ET

A trio of private equity giants are circling laboratory supplies and genetic testing company Life Technologies in what could be among the largest buyouts of the year.

The Blackstone Group, the Carlyle Group and Kohlberg Kravis Roberts, along with Singapore's sovereign wealth fund, are preparing an $11 billion bid for Life. The four were in talks late last night on terms, even after the deadline for bids passed. Should the private equity group manage to find the needed equity, Life would likely accept a bid after the deadline, according to Reuters.

The p.e. group will have to compete with a bid from Thermo Fisher Scientific, which submitted its offer yesterday.

The p.e. group as it exists is actually a merger of what could have been two competing consortia: Blackstone, Carlyle and Temasek Holdings had been working with TPG Capital, which has since dropped out, while KKR was working on a deal with other partners, who also backed out.


In Depth

Kettera Q&A: The Advantages of Alternative Investment Platforms

Oct 28 2016 | 5:52pm ET

The past several years have seen a distinct push towards easier and cheaper access...

Lifestyle

Midtown's Plaza District Fades As Manhattan Office Landscape Shifts

Nov 22 2016 | 6:32pm ET

Lower leasing costs, more efficient office space and the hope of projecting an image...

Guest Contributor

Nowhere to Hide: Why the Future of Asset Management Depends on Innovation

Nov 15 2016 | 6:55pm ET

Information technology has reshaped the asset management industry’s periphery,...

 

From the current issue of

Chicago-based independent futures brokerage and clearing firm R.J. O’Brien & Associates (RJO) has hired industry veteran Daniel Staniford as Executive Director, responsible for the firm’s institutional business development in New York and London.

AVAILABLE NOW at BARNES & NOBLE

NEWSTAND LOCATOR